Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 613,633 shares of the biopharmaceutical company’s stock after acquiring an additional 19,112 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $25,816,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Algert Global LLC boosted its position in shares of Ultragenyx Pharmaceutical by 46.9% during the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after acquiring an additional 23,580 shares during the last quarter. Bamco Inc. NY acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $2,666,000. Principal Financial Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after acquiring an additional 76,150 shares during the last quarter. Cerity Partners LLC purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $1,773,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 294 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

RARE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Canaccord Genuity Group boosted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Wedbush reissued a “neutral” rating and issued a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $91.71.

Ultragenyx Pharmaceutical Trading Up 0.8 %

Ultragenyx Pharmaceutical stock opened at $39.64 on Tuesday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $37.02 and a twelve month high of $60.37. The stock’s fifty day simple moving average is $42.23 and its 200-day simple moving average is $47.87. The firm has a market capitalization of $3.67 billion, a P/E ratio of -6.25 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $3,091,571.40. Following the transaction, the chief executive officer now owns 641,731 shares of the company’s stock, valued at $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John Richard Pinion sold 14,439 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the completion of the transaction, the insider now directly owns 107,766 shares in the company, valued at $4,536,948.60. This trade represents a 11.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,370 shares of company stock valued at $5,751,499. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.